L-NMe-Kyn

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: L-NMe-Kyn
• 英文别名: (2S)-4-(2-aminophenyl)-2-(methylamino)-4-oxobutanoic acid
• 化学式: C₁₁H₁₄N₂O₃
• 分子量: 222.244
• InChiKey: KXCPNOXPQXMREK-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  相思豆毒素 在 臭氧 、 盐酸 作用下， 以 溶剂黄146 为溶剂， 反应 18.03h， 以12%的产率得到L-NMe-Kyn
  参考文献：
  名称：

  Protease inhibitors from a water bloom of the cyanobacterium Microcystis aeruginosa

  摘要：

  Five new protease inhibitors, micropeptins SD944 (1), SD979 (2), SD999 (3) and SD1002 (4) and microginin SD755 (5) were isolated along with two known inhibitors, micropeptin SF995 (6) and microcin SF608 (7), from the hydrophilic extract of Microcystis aeruginosa. The planar structure of compounds 1-5 was determined by homonuclear and inverse-heteronuclear 2D-NMR techniques as well as high-resolution mass spectrometry. The absolute configuration of the asymmetric centers was studied using Marfey's method for HPLC. Compounds 1-4, 6 and 7 are serine-protease inhibitors while compound 5 was found to inhibit amino-proteases. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00141-7

文献信息

• IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：SHANDONG LUYE PHARMACEUTICAL CO., LTD.

  公开号：US20190169140A1

  公开（公告）日：2019-06-06

  A compound as an indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, and an application thereof in the field of IDO1-related diseases, and in particular a compound as shown in formula (I) and a pharmaceutically acceptable salts thereof.

  一种作为吲哌酮胺-2,3-二氧化酶1（IDO1）抑制剂的化合物，以及其在IDO1相关疾病领域中的应用，特别是如公式（I）所示的化合物及其药用可接受的盐。
• Isotopic methods for measurement of tryptophan and metabolites thereof
  申请人：ELECTROPHORETICS LIMITED

  公开号：US11320438B2

  公开（公告）日：2022-05-03

  Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.

  色氨酸降解是控制免疫反应的关键代谢途径，有证据表明，在癌症发展过程中，色氨酸代谢物的产生可能是免疫逃逸的基础，以自分泌方式促进癌细胞的恶性表型。本发明涉及测量质量标签标记的色氨酸及其代谢物的方法，以及使用标记的分子监测受试者的治疗效果和治疗后疾病复发情况、对患者进行分层和诊断受试者免疫反应抑制情况的方法。
• ISOTOPIC METHODS FOR MEASUREMENT OF TRYPTOPHAN AND METABOLITES THEREOF
  申请人：Electrophoretics Limited

  公开号：EP3368905A1

  公开（公告）日：2018-09-05
• [EN] ISOTOPIC METHODS FOR MEASUREMENT OF TRYPTOPHAN AND METABOLITES THEREOF<br/>[FR] PROCÉDÉS ISOTOPIQUES POUR MESURE DE TRYPTOPHANE ET DE SES MÉTABOLITES
  申请人：ELECTROPHORETICS LTD

  公开号：WO2017072368A1

  公开（公告）日：2017-05-04

  Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.
• [EN] ANTIBACTERIAL CYCLIC LIPOPEPTIDES<br/>[FR] LIPOPEPTIDES CYCLIQUES ANTIBACTÉRIENS
  申请人：VERSITECH LTD

  公开号：WO2017173932A1

  公开（公告）日：2017-10-12

  Cyclic lipopeptides having one or more modifications relative to daptomycin, and methods of making them are provided. The cyclic lipopeptides can be used as antibacterial agents. The daptomycin analogues are generated by chemical synthesis, which makes introduction of an unnatural amino acid and any modification into daptomycin possible. Pharmaceutical compositions and method of use thereof for the disclosed daptomycin analogues are also provided.